ArticleMateria socio-medica2025
New Anticoagulant Therapy as a Treatment for Pulmonary Thromboembolism in Patients During the COVID-19 Epidemic.
Article in Materia socio-medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary embolism is a frequent, serious and life-threatening complication that represents the embolization of mostly thrombotic material into the pulmonary arteries, with complete or partial occlusion of one or more of its branches. Objective: To analyze the effectiveness of new anticoagulants (NOAC) in the long-term treatment of pulmonary embolism (PE) in patients with and without COVID-19. Methods: Retrospective and descriptive analysis based on data from medical records in the period 2021-2023. from the Zenica Cantonal Hospital. Results: Data were collected from 160 respondents, of which 33 (20.6%) were COVID-19 positive and 127 (79.4%) were not. Subjects with COVID-19 in 12 (36.4%) cases had reference D-dimer values, while 21 (63.6%) had elevated values. 9.1% had elevated platelet values, 78.8% had reference values, and 12.1% had decreased values. Among subjects without COVID-19, 50 (39.4%) had reference values of D-dimer, while 77 (60.6%) had an increase. 1 (0.8%) of subjects had decreased platelet values, 118 (92.9%) had reference values, and 8 (6.3%) had increased platelet values. No subjects with decreased D-dimer values were recorded. Conclusion: DOAC therapy showed equal efficacy in the long-term treatment of pulmonary embolism in both study groups, regardless of whether the subjects had COVID-19 or not.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.